Streetbeat News

Analyst Ratings

BGNE

JMP Securities has initiated coverage on BeiGene (NASDAQ:BGNE) with a Market Outperform rating and set a price target of $288.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 9:42 am

SHAK

TD Cowen analyst Andrew Charles has reiterated a Buy rating on Shake Shack (NYSE:SHAK) and maintained a price target of $125.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 9:33 am

GES

Small Cap Consumer Research analyst Eric Beder has reiterated a Buy rating on Guess (NYSE:GES) and maintained a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 9:30 am

WDAY

Piper Sandler analyst Brent Bracelin has reiterated an Overweight rating on Workday (NASDAQ:WDAY) with a maintained price target of $285.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 9:07 am

AZPN

Piper Sandler has maintained a Neutral rating on Aspen Technology while raising the price target from $200 to $217.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 9:06 am

DAVA

Endava plc (NYSE:DAVA) is set to release its Q4 earnings on Sept. 19, with expected earnings of 30 cents per share, down from 71 cents a year ago, and projected revenue of $256.75 million. Analysts have adjusted their price targets, maintaining positive ratings but lowering expectations.

Portfolio Pulse from Avi Kapoor

September 18, 2024 | 6:57 am

BOOM

Stifel analyst Stephen Gengaro maintains a Buy rating on DMC Global (NASDAQ:BOOM) but lowers the price target from $19 to $17.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 9:06 pm

CTAS

Truist Securities has maintained a Buy rating on Cintas (NASDAQ:CTAS) and raised its price target from $212.5 to $225, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 9:04 pm

CAPR

Oppenheimer analyst Leland Gershell has maintained an 'Outperform' rating on Capricor Therapeutics and raised the price target from $14 to $15.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 9:02 pm

NARI

Inari Medical (NASDAQ:NARI) has been analyzed by 9 analysts over the past three months, with ratings ranging from bullish to bearish. The average 12-month price target is $58.78, down from $60.17. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Inari Medical's revenue growth is notable at 22.53%, but its net margin and ROA are below industry averages, indicating profitability challenges.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 9:01 pm